Login / Signup

Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study.

Fariba NematiLeanne De KoningDavid GentienFranck AssayagEmilie HenryKhadija Ait RaisGaelle PierronOdette MarianiMichèle NijnikoffGabriel ChampenoisAndré NicolasDidier MeseureSophie GardratNicolas ServantPhilippe HupéMaud KamalChristophe Le TourneauSophie Piperno-NeumannManuel J RodriguesSergio Roman-RomanDidier DecaudinPascale MarianiNathalie Cassoux
Published in: Current oncology (Toronto, Ont.) (2023)
Uveal melanoma is the most common primary intraocular malignancy in adults. Up to 50% of UM patients develop metastatic disease, usually in the liver. When metastatic, the prognosis is poor, and few treatment options exist. Here, we investigated the feasibility of establishing patient-derived xenografts (PDXs) from a patient's tumor in order to screen for therapies that the patient could benefit from. Samples obtained from 29 primary tumors and liver metastases of uveal melanoma were grafted into SCID mice. PDX models were successfully established for 35% of primary patient tumors and 67% of liver metastases. The tumor take rate was proportional to the risk of metastases. PDXs showed the same morphology, the same GNAQ/11, BAP1, and SF3B1 mutations, and the same chromosome 3 and 8q status as the corresponding patient samples. Six PDX models were challenged with two compounds for 4 weeks. We show that, for 31% of patients with high or intermediate risk of metastasis, the timing to obtain efficacy results on PDX models derived from their primary tumors was compatible with the selection of the therapy to treat the patient after relapse. PDXs could thus be a valid tool ("avatar") to select the best personalized therapy for one third of patients that are most at risk of relapse.
Keyphrases